Bill Castell, Joe Hogan, Thomas McLain, Guava Technologies EasyCyte, and Research and Markets Survey of Current Applications of Fluorescent Proteins in Drug Discovery | GenomeWeb

Migrations

General Electric said that Bill Castell, CEO of GE Healthcare, will retire next year. He will be replaced by Joe Hogan upon his retirement. The appointment was included in an announcement about the realigning of GE's businesses.


Thomas McLain has been appointed to the board of directors of the Biotechnology Industry Organization, effective June 21, 2005. McLain is one of 11 new board members, who will each serve two-year terms.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.